Introduction: Proarrhythmia and Drug Development {#s1}
================================================

Proarrhythmia---the triggering of arrhythmias following drug therapy---has been known for many decades as being caused by "anti"-arrhythmic cardiac drugs ([@B144]; [@B37]; [@B167]). This rare but lethal side-effect of drug therapy, however, is not restricted to anti-arrhythmic drugs, but occurs with a variety of other, non-cardiac drugs ([@B170]; [@B171]; [@B30]), and therefore is a major concern for patients, physicians, and the pharmaceutical industry. It has been estimated that around 20--60% of novel chemical entities have the potential to modulate the function of cardiac ion channels and therefore, to disturb normal cardiac electrical function ([@B29]). Depending on the nature of the drug-induced effects on ion channels function, proarrhythmia can be associated with prolongation or shortening of the QT interval (long QT syndrome, LQTS or short QT syndrome, SQTS, respectively) and/or with conduction disturbances.

For most drugs, proarrhythmia is assumed to be based on prolongation of cardiac repolarization as a result of drug-induced inhibition of cardiac potassium currents (mostly *I*~Kr~ current(s)/HERG-channels) ([@B134]). This acquired LQTS predisposes to Torsades-de-Pointes (TdP) polymorphic ventricular tachycardia that could lead to ventricular fibrillation and sudden cardiac death (SCD) ([@B56]; [@B134]; [@B44]). Although no less than 2--3% of all marketed drugs have the potential to induce LQTS ([@B147]), the (documented) incidence of potentially lethal drug-induced TdP is typically very low (1:10,000 for non-cardiovascular drugs) ([@B178]), and therefore very hard to predict reliably ([@B44]). In recent decades, TdP-induced SCD cases were associated with a wide range of commonly used drugs (anti-psychotics, anti-depressants, antihistamines, and antibiotics) ([@B56]; [@B134]; [@B44]) and many of them (such as cisapride, astemizole, terfenadine, grepafloxacin) have been withdrawn from the market ([@B41]; [@B148]; [@B45]).

As a response from the regulatory authorities, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines \[ICH-S7B, 2005 ([@B47]); ICH-E14, 2005 ([@B46])\] were proposed for rigorous safety testing to avoid similar unacceptable human fatalities (SCD) in association with pharmacological therapy of non-life-threatening pathologies. Unfortunately, no "gold"-standard proarrhythmia screening method exist. Therefore, current safety screening in industry rely on combined use of pre-clinical *in vitro* assessment of HERG function, action potential (AP) and *in vivo* ECG (QT) assays, *in silico* computational ([@B177]; [@B126]; [@B90]) risk prediction \[integrated risk assessment (IRA) approach\], and clinical ECG studies ([@B46]; [@B47]). Usually, different proarrhythmia markers and score systems \[see *Proarrhythmia ECG Markers for Temporal Instability of Repolarization (Used in In Vivo and In Vitro Models*)\] are employed to try to increase the predictive value of the overall assessment ([@B61]; [@B60]; [@B134]; [@B85]) with moderate to limited success ([@B130]).

Drug-induced *I*~Kr~/HERG blockade used to be considered the most important factor responsible for proarrhythmia formation. Therefore, for a long time, safety tests largely focused on detection of HERG-blocking potential of test compounds. As a result, this approach led to elimination of potentially promising drug candidates from the developmental pipeline solely on the basis of their potential to block the HERG channel ([@B21]; [@B17]; [@B133]). HERG blockade plays an inevitably important role in proarrhythmia formation ([@B178]; [@B54]); though, HERG block on its own does not necessarily lead to proarrhythmia since simultaneous reduction in other ion currents---such as in *I*~Na~ or *I*~Ca~---that may have anti-arrhythmic effects could modify the overall proarrhythmic potential of the drug ([@B156]; [@B12]; [@B153]; [@B2]). On the other hand, compounds without HERG-blocking characteristics may still have proarrhythmic side effect *via* the inhibition of repolarizing ion currents such as the slow delayed rectifier potassium current *I*~Ks~ or the inward rectifier potassium current *I*~K1~ ([@B133]; [@B137]; [@B76]; [@B132]). Based on the above, pharmaceutical industry has started the Comprehensive *in vitro* Proarrhythmia Assay (CiPA) initiative to work with validated assays, and to fill gaps in the internal proarrhythmia assessment with the overall goal to comply with the ICH-S7B guidelines. This new approach consists of three main elements: 1) systematic measurement of the effect of drug candidates on multiple human cardiac ion currents (*I*~Kr~, *I*~Ks~, *I*~Na,peak~, *I*~Na,late~, *I*~K1~, *I*~to~, *I*~Ca,L~) in heterologous expression systems ([@B79]; [@B23]; [@B27]), 2) *in silico* integration of these ion channel effects, and 3) evaluation of the drug effect on integrated biological systems such as on stem-cell-derived cardiomyocytes ([@B27]; [@B28]; [@B65]). According to a recent survey on current industrial safety screening practice ([@B7]), 90% of the pharmaceutical companies use cell lines expressing cardiac ion channels, 50--60% of them perform ion channel binding assays, cardiac AP recordings or use human induced pluripotent stem cell-derived cardiomyocytes, and only around one-third of them integrate their electrophysiological results into an *in silico* model in order to better predict the drug effect on AP shape and duration. The CiPA initiative is undoubtedly a promising approach; however, its overall implementation is not sufficient yet.

The other major challenge in proarrhythmia screening derives from the huge inter-individual differences in susceptibility to arrhythmia, which makes the overall risk stratification particularly difficult. Gender, sex hormones, K^+^ homeostasis, and---most importantly---certain diseases highly influence the cardiac "repolarization reserve", defined as the ability of cardiomyocytes to maintain sufficient repolarization despite repolarization-prolonging (mostly K^+^ channel blocking) effects *via* compensatory increase of non-affected "reserve" outward K^+^ currents ([@B135]; [@B159]).

Apart from a decrease in serum K^+^ concentration that results in a massive prolongation of cardiac repolarization, cardiovascular and metabolic diseases such as congestive heart failure ([@B78]), cardiac hypertrophy, hypertrophic and dilated cardiomyopathy ([@B31]), ischemia ([@B36]), congenital LQTS ([@B39]), or diabetes mellitus ([@B101]; [@B168]) play the most important role in decreasing repolarization reserve capacity and thereby in increasing susceptibility to proarrhythmia.

Despite the fact that drug-induced TdP occur mostly in patients with reduced cardiac repolarization reserve, current safety assessments rely still mainly on tests performed on healthy animals with intact repolarization or on their tissues/cells ([@B46]; [@B47]). Consequently, new animal models, (i) with increased sensitivity to channel blockers other than only HERG, such as *I*~Ks~ or *I*~K1~, and (ii) representing different degrees of impairment in their cardiac repolarization reserve were suggested to employ in proarrhythmia research ([@B64]).

Sex hormones also can significantly alter the individual\'s repolarization reserve capacity and therefore affect susceptibility to arrhythmia. Women are at higher risk for drug-induced prolongation of repolarization and drug-induced TdP ([@B86]; [@B13]; [@B169]; [@B51]). This is due to sex hormone effects on cardiac ion currents/channels ([@B173]; [@B113]): estrogen prolongs cardiac repolarization by decreasing *I*~Ks~ ([@B35]) and *I*~Kr~ ([@B81]; [@B3]) and by increasing *I*~Ca,L~ ([@B116]; [@B117]) and NCX expression ([@B24]); therefore, estrogen reduces repolarization reserve and favors drug-induced arrhythmia. In contrast, testosterone and progesterone both increase repolarization reserve by increasing *I*~Ks~ \[testosterone ([@B91])/progesterone ([@B48])\], *I*~K1~ and *I*~Kr~ (testosterone) ([@B91]), decreasing *I*~Ca,L~ \[testosterone ([@B48])/progesterone ([@B116]; [@B117])\], and upregulating SERCA expression \[progesterone ([@B116]; [@B117]; [@B106])\], thereby exerting a protective, "anti-arrhythmic" effect against drug-induced proarrhythmia ([@B116]; [@B117]). These observations have consequences for proarrhythmia research, as female animal models (or animal models with altered hormonal state) might be particularly sensitive in detecting potential ion channel-blocking properties of drug candidates.

In this review, we first give an overview about currently employed proarrhythmia markers, the importance of the choice of species for proarrhythmia research, and the advantages and disadvantages of currently used *in vivo* proarrhythmia models, followed by a detailed description of novel transgenic LQTS rabbit models. Finally, we provide a brief outlook on possible future directions and novel models in the field.

Proarrhythmia ECG Markers for Temporal Instability of Repolarization (Used in *In Vivo* and *In Vitro* Models) {#s1_1}
--------------------------------------------------------------------------------------------------------------

Based on the clinical observations that TdP mostly occurred in the setting of prolongation of ventricular repolarization/QT prolongation ([@B56]; [@B134]), preclinical and clinical safety tests have for a long time focused on QT prolongation as a surrogate marker for TdP risk ([@B47]). However, it has been known for some time that prolongation of repolarization does not always equally increase pro-arrhythmic risk since numerous drugs that block *I*~Kr~/HERG and prolong QT rarely cause TdP---while others causing less pronounced QT prolongation carry a significant pro-arrhythmic risk ([@B180]; [@B175]; [@B136]; [@B153]; [@B146]). Indeed, the extent of QT prolongation did not predict serious ventricular arrhythmias and/or SCD in different rabbit and dog experimental models ([@B1]; [@B153]; [@B146]; [@B87]; [@B68]) or in patients with ([@B149]; [@B179]; [@B99]; [@B58]; [@B59]) or without ([@B38]; [@B82]; [@B127]) congenital/structural heart disease. Thus, these safety tests can yield either false positive results, halting the development of a promising new drug ([@B136]; [@B62]) or false negative results, causing harm to patients with increased susceptibility to arrhythmia. Therefore, there is an unmet need for (i) improved identification of patients at elevated risk for drug-induced arrhythmia ([@B73]) and (ii) novel ECG markers with better predictive value for pro-arrhythmic drug adverse effects.

A number of different electrophysiological parameters have been investigated as non-invasive prognostic markers for TdP and SCD risk evaluation both in animal experiments and in the clinical setting. These novel markers mostly derive from the original work by Hondeghem *et al*., suggesting the assessment of AP triangulation, instability, and dispersion ([@B61]). These markers were later supplemented by evaluation of disturbances in cardiac wavelength ([@B62]; [@B63]). The importance of an increased spatial (transmural, apico-basal, or inter-ventricular) dispersion of repolarization in reentry-based arrhythmia formation was further supported by other studies ([@B6]; [@B9]; [@B53]). Therefore, T~peak-end~---the length from the beginning of the T wave (T~p~) to the end (T~e~) on ECG---that reflect the transmural dispersion of repolarization was suggested to use as an indicator of arrhythmic risk, although, no clear consensus about the value of this parameter has been reached so far ([@B6]; [@B9]; [@B103]). Of note, dispersion of repolarization was recently identified (experimentally and by computational modeling) as cause for triggered activity/EAD formation, further enhancing the need to assess dynamic dispersion of repolarization noninvasively ([@B94]).

The temporal instability of cardiac repolarization can be described by different variables characterizing the small beat-to-beat fluctuations in the QT interval as QT variability \[for a recent review see ([@B10])\]. Beat-to-beat variability of repolarization can be quantified by calculating the short-term variability of the QT (STV~QT~) ([@B153]). First in the chronic AV-block dog model, then in other animal experimental proarrhythmia models ([@B153]; [@B87]; [@B68]) and in clinical settings ([@B57]; [@B58]; [@B59]; [@B120]), it has been repeatedly shown that STV~QT~ has a higher predictive value for proarrhythmia risk than the overall prolongation of repolarization (QT duration). STV~QT~ has been used in several studies to confirm the safety of different drugs ([@B121]; [@B4]; [@B157]), to characterize pro-arrhythmic drug effects ([@B153]; [@B155]; [@B80]), and to assess temporal repolarization instability in patients with co-morbidities associated with repolarization disturbances ([@B123]; [@B124]; [@B125]).

Based on the above, it is justified and required to assess and validate measures of temporal QT variability in animal experimental models of proarrhythmia.

Current *In Vivo* Models for Pre-Clinical Proarrhythmia Safety Screening and Their Limitations {#s2}
==============================================================================================

Choice of Models: Species Differences in Repolarizing Currents {#s2_1}
--------------------------------------------------------------

Cardiac electro-mechanical function shows large inter-species variability. These species differences are especially striking in regard to cardiac repolarization that is governed by tightly regulated activities of various inward and outward ion currents.

Small rodents like mice or rats are commonly used animals for studying ischemia-induced arrhythmias (which are often linked to conduction properties), since cardiac conduction properties in these animals are governed by Na^+^ currents, Ca^2+^ currents, and connexin function that are very similar to those in human ([@B32]; [@B74]). Furthermore, they have the advantage of low cost, short life-cycle, and their genetic manipulation is much easier than that in larger animals (see *Genetically Modified Mouse Models With Reduced Repolarization Reserve*). On the other hand; however, they have limited value in studying (prolonged) repolarization-related arrhythmogenesis: in mice and rats the fast and slow transient outward (*I*~to~), and the delayed rectifier (*I*~K,slow1~ and *I*~K,slow2~) ([@B172]; [@B18]; [@B92]) voltage-gated potassium currents play a major role in repolarization---while in dogs, rabbits, and humans the rapid and slow delayed rectifier potassium currents (*I*~Kr~ and *I*~Ks~) are the major determinants of cardiac repolarization ([@B160]; [@B111]; [@B109]; [@B52]; [@B141]; [@B176]). The exact role of *I*~Kr~ and *I*~Ks~ in small rodents is still not well known and controversial ([@B109]; [@B52]; [@B141]; [@B176]). As a result, the shape of their AP is different compared to larger animals and humans (triangular shape vs. rectangular AP with prominent plateau phase) ([@B109]; [@B52]; [@B141]; [@B176]), as well as their pharmacological responses to proarrhythmic potassium channel blocking drugs ([**Figures 1A, B**](#f1){ref-type="fig"}).

![Species differences in repolarizing ion currents. **(A)** Representative action potential (AP) recordings \[modified from ([@B139]; [@B14])\] and **(B)** schematic illustration of the main repolarizing ion currents in mouse, rabbit, dog, and human cardiomyocytes \[modified from ([@B110])\]. Panel **(C)** shows species differences in I~Ks~, I~Kr~, and I~K1~ in rabbit, dog, and human.](fphar-11-00853-g001){#f1}

Acute *I*~Kr~-blocker administration, for example, prolongs repolarization in dogs, rabbits, and humans but not in mice or rats ([@B161]; [@B108]; [@B71]; [@B176]). Chronic administration of the *I*~Kr~-blocker dofetilide that prolongs repolarization in larger animals and human subjects by blocking HERG channels on the other hand, lengthen repolarization in mice---at least partly---by increasing *I*~Na,L~ (via phosphoinositide 3-kinase pathway) ([@B176]). Based on the above, mice and rats have serious limitations in drug-induced proarrhythmia research with little translational potential.

In contrast, the function and gating kinetics of various cardiac potassium channels are very similar in dogs, rabbits, and humans with *I*~Kr~ and *I*~Ks~ as main repolarizing ion currents in all three species ([@B160]; [@B111]; [@B109]; [@B71]), with slight inter-species differences: In humans and dogs---just as in most mammals---*I*~to~ is formed of two distinct subtypes named as *I*~to,fast~ and *I*~to,slow~---with fast and slow recovery from inactivation, determined by Kv3.4 and Kv1.4, respectively ([@B131]) as opposed to rabbits, where *I*~to,slow~ is the primary transient Kv current in the left ventricle ([@B43]), while in the right ventricle *I*~to,fast~ and its role in LQT1 related arrhythmogenesis has recently been confirmed ([@B26]). The repolarization capacity of rabbits and dogs is more robust than that in humans due to higher *I*~K1~, *I*~Kr~, and *I*~Ks~ current densities ([@B71]; [@B66]) ([**Figure 1C**](#f1){ref-type="fig"}).

In summary, the rabbit has a prominent role in arrhythmia research, since: (i) the shape of AP ([@B160]) and the function and gating kinetics of the underlying cardiac ion channels/currents ([@B111]), (ii) the myocardial mechanical function ([@B72]), (iii) the relative effective heart size relating cardiac mass to the frequency of VF ([@B128]), and (iv) their responses to pharmacological interventions ([@B55]) show very close resemblance to human cardiac physiology. Based on the above-described species differences in various ion currents, the rabbit could have advantages over dog models when testing the proarrhythmic potential of drugs with *I*~Kr~, *I*~Ks~, or *I*~K1~-blocking properties since they show very good similarity to human physiology in these currents and are cheaper, easier to handle, and to breed than dogs and can be modified genetically. Dogs or guinea pigs, on the other hand, may be better suited to use for studying arrhythmogenesis in which *I*~to~-inhibition plays an important role.

*In Vivo* Proarrhythmia Models With Reduced Repolarization Reserve {#s2_2}
------------------------------------------------------------------

Both drug-induced and genetically modified animal models with impaired repolarization reserve have been generated in various species (such as dogs, mice, and rabbits) and utilized to investigate drug-induced proarrhythmia and its underlying mechanisms \[reviewed in ([@B142]; [@B83])\]. In addition, animal models with cardiac diseases---e.g. chronic heart failure, hypertrophic cardiomyopathy, diabetes mellitus etc.---leading to electrical remodeling-associated alterations of repolarization reserve can be used for proarrhythmia research. These models have the advantage that they mimic some of the diseases that also predispose human patients to drug-induced arrhythmias.

One main shortcoming of drug-induced animal models, however, is the fact that drugs have to be administered continuously to sustain the drug-induced reduction of repolarization reserve, thus impeding detailed investigation of (long-term) proarrhythmia in free-moving, non-anesthetized animals.

One main short-coming of genetically modified mouse models---the only genetic models with reduced repolarization reserve available until 2008---are the pronounced species differences in cardiac electrophysiology with different ion currents conveying cardiac repolarization in human and murine cardiomyocytes ([@B160]; [@B111]; [@B109]; [@B71]) as highlighted in the subchapter above.

High cost and need for special technical expertise for example are considered as main shortcomings for the generation of disease-related animal models with cardiac electrical remodeling.

### Drug-Induced Animal Models With Reduced Repolarization Reserve {#s2_2_1}

One frequently used drug-induced model is the methoxamine-sensitized rabbit model: anesthetized rabbits are sensitized with the selective α-adrenoceptor-agonist methoxamine, which makes them particularly prone to develop drug-induced ventricular tachycardia when exposed to HERG/*I*~Kr~-blocking drugs ([@B22]; [@B20]). The choice of the anesthetic regimen, however, strongly influences the extent of proarrhythmia development in this model---as the different anesthetics all have different intrinsic cardiac ion channel-blocking properties ([@B22]; [@B67]), indicating the importance of the degree of ion channel blockade in these "mixed" drug-induced models. Pro- and anti-arrhythmic properties of various different drugs have been tested and classified as having a low, intermediate, or high pro-arrhythmic potential for drug-induced TdP using this model ([@B34]; [@B20]; [@B68]; [@B107]; [@B158]). However, as the model depends on α-adrenoceptor sensitization, the full extent of pro-arrhythmic potential of drugs that concomitantly block *I*~Kr~ and α-adrenoceptors (such as quinidine, cisapride, quinolone) may not be fully appreciated by this model ([@B22]; [@B107]).

Other frequently employed drug-induced rabbit models are based on the *ex vivo* blockade of HERG/*I*~Kr~ by E-4031 ([@B25]; [@B100]; [@B129]; [@B84]) or by dofetilide ([@B42]; [@B33]; [@B122]), thus generating a drug-induced rabbit model representing LQT2 characteristics. Similar to the genetic reduction of *I*~Kr~ in congenital LQT2, the drug-blockade of *I*~Kr~ by E-4031 or dofetilide leads to a high propensity for arrhythmia development in *ex vivo* Langendorff-perfused rabbit hearts---particularly when perfused with low K^+^ and Mg^2+^ solutions ([@B100]; [@B104]). Similarly, QTc prolongation and arrhythmia susceptibility is particularly high when HERG/*I*~Kr~ blockade is combined with KvLQT1/*I*~Ks~ blockade by HMR-1556 ([@B87]) ([**Figure 2A**](#f2){ref-type="fig"}).

![Pro-arrhythmia detection with acquired LQT rabbit and chronic AV-block dog models. **(A)** Left panel: The QTc interval was significantly prolonged by the I~Kr~ blocker dofetilide and was further prolonged by the combination of dofetilide and the I~Kr~ blocker HMR1556 given in any order, while I~Ks~ block alone did not prolong the QTc in anesthetized rabbits. Right panel: I~Kr~ block caused TdP in some of the animals, I~Ks~ block alone did not induce TdP in anesthetized rabbits. Importantly, combined acute pharmacological block of I~Ks~ and I~Kr~, given in any order, caused a significant increase in TdP incidence. \#p \< 0.05 vs. baseline control in the same group; \*p \< 0.05 vs. dofetilide. N=7-11 animals/group. CTRL: Control, DOF: Dofetilide, HMR: HMR-1556. Modified from ([@B87]). **(B)** In right ventricular cardiomyocytes isolated from dogs with chronic AV-block and marked myocardial hypertrophy, I~Ks~ tail current density was reduced by approximately 55% (n=9), while I~Kr~ tail current density was reduced by 45% (n=14) compared to those isolated from control animals. \*p \< 0.05 vs. control myocytes. Modified from ([@B163]). **(C)** Standard bipolar ECG lead recordings illustrating a marked difference in the arrhythmogenic response to administration of the selective I~Kr~ blocker D-sotalol in dogs with acute (left panel) and chronic AV-block (right panel). The pacing protocol involved a basic pacing cycle length (CL) of 1730 ms in acute AV block, and 1800 ms spontaneous idioventricular CL in chronic AV-block. Arrhythmia provocation included a short/long/short sequence at 600 ms CL for 4 beats followed by 2 paced beats with 1200 and 350 ms cycle lengths. No TdP was observed in acute AV-block dogs, while 60% of animals with chronic AV-block exhibited TdP. Modified from ([@B166]).](fphar-11-00853-g002){#f2}

### Genetically Modified Mouse Models With Reduced Repolarization Reserve {#s2_2_2}

Despite apparent differences between human and mouse electrophysiology---e.g., different ion currents conveying cardiac repolarization in human and murine cardiomyocytes, a different shape of the AP, and a magnitude-faster heart rate in mice \[reviewed in ([@B111]); ([@B142]); ([@B8])\], the first transgenic and knock-out animal models of LQTS were mouse models ([@B96]). The reason for this was that genetic manipulation has for a long time nearly exclusively been feasible in mice and not in other larger mammals such as rabbits. Transgenic models based on mutations in human potassium channel genes or knock-out/knock-in models of mouse potassium channel genes could only partially mimic the characteristics of human patients with impaired repolarization reserve \[reviewed in detail in ([@B110]); ([@B83]); ([@B182])\], while genetically modified mouse models with mutations in the sodium channel gene (SCN5A; LQT3) more closely mimic the human long QT disease phenotype with AP duration (APD) and QT prolongation as well as spontaneous life-threatening ventricular arrhythmia ([@B112]; [@B40]), since *SCN5A* drives the majority of depolarizing Na^+^ currents in both human and murine cardiomyocytes ([@B32]).

None of these mouse models, however, have been systematically used for proarrhythmia research---mainly due to the fact that *I*~Kr~ current (the most frequent target for drugs inducing proarrhythmia) plays no major role in cardiac repolarization in mice.

### Animal Models With Structural/Electrical Remodeling and Reduced Repolarization Reserve {#s2_2_3}

Several experimental animal models of different species exist that are characterized by impaired repolarization reserve associated with cardiac structural and/or electrical remodeling. The most thoroughly characterized of these is the canine cardiac volume overload model with chronic atrioventricular block ([@B165]). Three months following AV-node ablation, these dogs exhibit severe bradycardia and eccentric, biventricular myocardial hypertrophy without heart failure ([@B166]). Importantly, the model is characterized by heterogeneous prolongation of APD at baseline and further APD-prolongation and early afterdepolarization (EAD) development upon administration of *I*~Kr~-blocker *d*-sotalol, indicating increased susceptibility to drug-induced TdP ([@B166]) ([**Figure 2C**](#f2){ref-type="fig"}). A significant downregulation of potassium currents, including *I*~Ks~---a key player in ventricular repolarization reserve in mammals including humans ([@B161]; [@B164]; [@B70])---was observed in both left and right ventricular cardiomyocytes isolated from dogs with chronic AV block ([@B163]) ([**Figure 2B**](#f2){ref-type="fig"}). In addition, *I*~Kr~ density was reduced by 45% in right ventricular myocytes, while left ventricular (LV) *I*~Kr~ density was unchanged ([@B163]).

The ability of the model to detect drug-induced TdP was validated ([@B151]) with several drugs such as the H~1~ antihistamine terfenadine ([@B105]), the antipsychotic drug sertindole ([@B152]), and the D~2~ dopamine receptor antagonist sulpiride ([@B150]). Moreover, with this model, it was demonstrated for the antibiotics moxifloxacin and azithromycin that QT prolongation does not necessarily cause TdP ([@B154]). An important advantage of this model is an improved proarrhythmia reproducibility within the same experimental animal ([@B162]). There are, however, some disadvantages that may prevent this model from becoming widely used for proarrhythmia research: it is a relatively expensive, time consuming (at least 3 months have to pass before ventricular hypertrophy and increased susceptibility to arrhythmia develops) and low throughput method that requires special technical expertise for performing AV-node ablation ([@B166]).

In diabetes, a moderate remodeling-associated QT prolongation has been shown ([@B50]), and diabetes has been associated with increased risk of SCD ([@B49]), indicating the patients\' higher susceptibility to proarrhythmia. Similarly, in rabbit and dog models of diabetes mellitus, a mild prolongation of repolarization and a decreased repolarization reserve due to downregulation of *I*~Ks~ and *I*~to~ (reversible by insulin treatment) were observed ([@B88]; [@B89]). The authors are not aware, however, of any published studies using experimental diabetes animal models in species with repolarization relevant to human (i.e. not mice or rats) for testing pro-arrhythmic effects of drugs in this "patient" cohort.

Transgenic LQTS Rabbit Models With Impaired Repolarization Reserve (LQTS) {#s3}
=========================================================================

Since cardiac electrophysiological characteristics of the rabbit is much closer to humans than that of mice or rats ([@B160]; [@B111]; [@B109]; [@B71]),---similar potassium currents (mainly I~Kr~ and I~Ks~) convey the cardiac repolarization in rabbits and humans---transgenic LQTS rabbit models were generated as soon as it became technically feasible ([@B16]) to better mimic pathophysiology of (human) LQTS patients with decreased repolarization reserve, who are most vulnerable to the development of drug-induced arrhythmias.

Generation of Transgenic LQTS Rabbit Models {#s3_1}
-------------------------------------------

To generate transgenic LQTS rabbit models with impaired repolarization reserve, the so-called "dominant-negative" transgenic strategy, which describes the fact that the co-assembly of mutated and normal channel subunits completely disrupts the overall ion channel function, was utilized to decrease the expression of functionally normal repolarizing potassium channel proteins. All available transgenic LQTS rabbit models have been engineered by beta-myosin heavy chain promoter-driven cardio-selective over-expression of mutated human genes encoding for voltage-gated K^+^ channels such as *KCNQ1*/KvLQT1 (KvLQT1-Y315S, LQT1)*, KCNH2*/HERG (HERG-G628S, LQT2), or *KCNE1*/minK (KCNE1-G52R) ([@B19]; [@B97]).

To generate the transgenic founder animals, the pronuclear microinjection technique was used. Superovulation was induced in wild-type (WT) rabbits using hormonal stimulation with FSH and GnRH-analogues, and inseminated oocytes were microinjected with transgenic mutant DNA-constructs and re-implanted into foster mothers ([@B19]; [@B97]). Mating of the resulting transgenic F0 founders with female WT rabbits resulted in vertical transmission with 50% transgenic and 50% WT offspring. To generate double-transgenic LQT2--5 rabbits, LQT2 male and LQT5 female rabbits were cross-bred ([@B64]).

Electrophysiological Characteristics and Arrhythmogenic Mechanisms in the Transgenic LQTS Models {#s3_2}
------------------------------------------------------------------------------------------------

In LQT1 or LQT2 rabbit cardiomyocytes the repolarizing potassium currents *I*~Ks~ (LQT1) or *I*~Kr~ (LQT2), respectively, are completely eliminated. This results in a prolongation of APD on the cellular and whole heart levels and a prolongation of ventricular refractoriness and QT interval duration *in vivo* ([@B19]; [@B115]). This prolongation of APD/QT is particularly pronounced at slower heart rates, leading to a steeper QT/RR ratio---particularly in LQT2 ([@B19]) ([**Figures 3A--C**](#f3){ref-type="fig"}). Moreover, these models demonstrate an increased temporal instability of QT duration with an increased STV~QT~ ([@B64]) and spontaneous polymorphic VT in LQT2 \[158\] ([**Figure 3D**](#f3){ref-type="fig"}).

![Baseline electrical characteristics of transgenic LQTS rabbits. **(A)** Upper panel: IV-curves of I~Ks~ steady (left)/tail (right) and I~Kr~ steady (left)/tail (right) in cardiomyocytes isolated from wild-type (WT), LQT1, and LQT2 rabbit hearts, indicating loss of I~Ks~ in LQT1 and loss of I~Kr~ in LQT2 \[modified from ([@B19])\]. Lower panel: IV-curves of I~Ks~ in absence and presence of 5 µM forskolin in WT or transgenic LQT5 rabbit ventricular myocytes. Bar diagrams illustrate a reduced deactivation time constant in transgenic LQT5 ventricular myocytes \[modified from ([@B97])\]. **(B)** Representative ECG tracings indicating differences in QT interval in WT, LQT1, LQT2, and LQT5 rabbits \[ECG from WT, LQT1 and LQT2 modified from ([@B19])\]. **(C)** QT/RR relationship assessed with telemetric ECG in free moving rabbits: WT, LQT1, and LQT2 in upper panel \[modified from ([@B19])\], in lower panel in WT and LQT5 \[modified from ([@B64])\]. **(D)** ECG and blood pressure tracing of LQT2 rabbit with spontaneous ventricular torsade-de-pointes (TdP) tachycardia \[modified from ([@B19])\]. \*p \< 0.05 vs. WT.](fphar-11-00853-g003){#f3}

In transgenic LQT5 rabbit cardiomyocytes, in contrast, the biophysical properties of *I~Ks~* and *I~Kr~* are altered with accelerated deactivation kinetics ([@B97])---but overall *I~Ks~* and *I~Kr~* current densities are not reduced. Consequently, these rabbits exhibit only a partial phenotype with no significant prolongation of whole heart APD ([@B97]; [@B64]), and only a very slightly prolonged QT interval at baseline without changes in QT/RR ratio ([@B97]; [@B64]) ([**Figures 3A--C**](#f3){ref-type="fig"}), but exhibit an increased short-term beat-to-beat variability of the QT ([@B97]). Due to their reduced repolarization reserve, the phenotype can be augmented by the *I*~Kr~-blocking drug dofetilide, which further increased short-term variability of QT and promoted drug-induced VT ([@B97]).

Studies in transgenic LQT1 and LQT2 rabbits highlight the major role of an enhanced (spatial and temporal) dispersion of repolarization in LQTS-related arrhythmogenesis: in LQT2 rabbit hearts, an increased spatial dispersion of APD was observed throughout left and right ventricles ([@B19]; [@B118]) ([**Figure 4A**](#f4){ref-type="fig"}). Dispersion of repolarization can also occur in a dynamic spatio-temporal fashion with pronounced beat-to-beat alternations and "out-of-phase" heterogeneities between adjacent regions, the so-called "discordant alternans". In transgenic LQT2 rabbit hearts, this discordant alternans developed at physiological heart rates and preceded VT/VF formation ([@B183]). VT/VF were easily inducible with LV epicardial stimulation ([@B19]), and, importantly, LQT2 rabbits even developed spontaneous polymorphic VT and SCD ([@B19]; [@B117]), thus representing the first transgenic animal models mimicking the complete electrical phenotype of LQT2. Transgenic LQT1 rabbits with a more homogeneously prolonged APD without substantial dispersion of repolarization within the LV at physiological/normal heart rates, in contrast, developed no spontaneous VT or SCD ([@B19]). When LQT1 hearts were further stressed, however, by continuous tachypacing or AV-ablation to induce cardiac tachymyopathy ([@B84]), or complete AV-block ([@B77]), respectively, APD dispersion increased, spatially discordant alternans developed and VT/VF was easily inducible or occurred spontaneously. Transgenic LQT5 rabbits demonstrated an increased apico-basal APD heterogeneity compared to healthy WT hearts at baseline---despite their overall "normal" APD ([@B64]).

![Mechanisms of arrhythmogenesis in transgenic LQT2 rabbits. **(A)** Upper panel (i): Bar graphs of action potential durations (APD) and dispersion of APD (ΔAPD) in Langendorff-perfused hearts of WT, LQT1, and LQT2 rabbits indicate longer APD and increased APD dispersion in LQT2 hearts, \*p \< 0.05 \[modified from ([@B19])\]. Lower panel (ii): optical mapping APD map (left; indicated are isochrones of APD, in ms) and activation maps (right) of initial beats of ventricular tachycardia/fibrillation (VF) in an estradiol-treated LQT2 heart indicate reentry formation (indicated by red arrows) in line with the regional APD heterogeneities \[modified from ([@B117])\]. **(B)** Representative trace of Ca^2+^ oscillations and early afterdepolariaztion (EAD) in estradiol-treated LQT2 rabbit heart after AV-node ablation and bolus application of isoproterenol (140 nM). Black line indicates changes in voltage fluorescence signal (Vm); red line indicates changes in Ca^2+^ signal \[modified from ([@B117])\].](fphar-11-00853-g004){#f4}

In addition to increased temporal instability and regional heterogeneity of repolarization that form the electrical "substrate" that facilitates re-entry formation, an increased sympathetic nervous system activity serves as "trigger" for EADs in long QT-related arrhythmogenesis ([@B5]; [@B19]; [@B183]). In LQT2 cardiomyocytes, beta-adrenergic stimulation related EADs developed during sudden sympathetic surge ([**Figure 4B**](#f4){ref-type="fig"}), while continuous perfusion with beta-agonist isoproterenol prevented EAD formation ([@B19]; [@B93]; [@B117]). In LQT1 cardiomyocytes, in contrast, continuous beta-adrenergic stimulation facilitated the occurrence of EADs ([@B93]). Different time courses in sympathetic activation of cardiac ion currents may explain why different sympathetic modes (sudden surge vs. continuous activation) are associated with arrhythmia formation in different genotypes of LQTS: upon sympathetic stimulation, beta-1 receptor mediated activation of *I*~Ca,L~---that may elicit EADs---is faster than the activation of *I*~Ks~---that shortens APD in LQT2 and acts as anti-arrhythmic mechanism upon continuous adrenergic stimulation in LQT2. In addition, different modes of arrhythmia initiation and maintenance in different LQTS genotypes were identified. While in LQT2, reentry formation played an important role ([@B19]), in LQT1 hearts, a novel mechanistic concept of LQTS-related arrhythmogenesis was identified: arrhythmia was initiated by focal excitations arising particularly from the RV and was maintained by multiple shifting excitation foci and bi-excitability ([@B77]).

Similarly, as in the LQT5 rabbit models, the phenotype and proarrhythmia could be augmented by ion channel blocking drugs and endogenous factors (as highlighted in the following subchapters).

Pro-Arrhythmic Effects of Endogenous Factors (Hormones and Metabolites) in Transgenic LQTS Rabbit Models With Impaired Repolarization Reserve {#s3_3}
---------------------------------------------------------------------------------------------------------------------------------------------

Pronounced sex differences in arrhythmic risk have been identified in patients with congenital and acquired, drug-induced LQTS with a higher risk for cardiac arrhythmic events in women after puberty than men ([@B86]; [@B95]; [@B13]; [@B169]; [@B51]; [@B174]). Moreover, while the risk for long QT-related arrhythmia is reduced during pregnancy ([@B145]), it is particularly high risk during the postpartum (particularly in LQT2 patients) ([@B143]). In addition, more pronounced QT-prolongation and arrhythmias are observed during luteal than follicular phases of the menstrual cycle ([@B138]), strongly suggesting that changing sex hormone levels may affect LQTS-related arrhythmogenesis. This has consequences for proarrhythmia research, as female animal models might be particularly sensitive in detecting potential ion channel-blocking properties of drug candidates.

In transgenic LQT2 rabbits, spontaneous ventricular arrhythmia and SCD also often occurred during postpartum ([@B19]; [@B117]), suggesting the existence of similar arrhythmia-triggering mechanisms as in human LQTS patients. In these models, estradiol exerted a pro-arrhythmic effect with an increased incidence of lethal polymorphic TdP due to changes in APD dispersion and increased EAD formation upon pro-arrhythmic sympathetic stimuli, while progesterone had an anti-arrhythmic, protective effect that was based on a shortening of cardiac refractoriness, a reduced formation of EAD, and stabilizing Ca^2+^ effects (decreased *I*~Ca,L~ density, increased SERCA expression) ([@B117]). These studies suggest that progesterone-based therapies may be considered as novel anti-arrhythmic approaches in female LQTS patients; and might be considered as therapeutic add-on in cases of severe drug-induced long-QT related proarrhythmia ([@B117]). As estradiol-treated hearts are particularly sensitive to proarrhythmia, their use in proarrhythmia research, in contrast, might increase sensitivity to identify candidates with a pro-arrhythmic potential.

Similarly, the postpartum-related hormones oxytocin and prolactin decreased *I*~Ks~ current densities, thereby prolonging the APD/QT further and predisposing the heart to arrhythmias ([@B119]).

Hormones as well as other endogenous factors such as certain metabolites may impact on repolarization reserve: it has been demonstrated that (genetic) metabolic disturbances such as propionic acidemia can also cause acquired LQTS ([@B75]; [@B11]; [@B69]), thus rendering patients at increased risk for additional drug-induced proarrhythmia. Using rabbit models of LQTS, we could identify a propionic acid-induced reduction of *I*~Ks~ current densities as underlying mechanism ([@B15]).

Transgenic LQTS Rabbit Models for Better Detection of Drug-Induced Ventricular Arrhythmias {#s3_4}
------------------------------------------------------------------------------------------

Drug-induced proarrhythmia is based on regionally heterogeneous prolongation of cardiac repolarization caused by various groups of drugs blocking multiple ion channels. As it most-often occurs in patients with reduced repolarization reserve (see above), the use of various transgenic LQTS rabbit models ([@B19]; [@B97]) with increased sensitivities to potassium channel blocking effects and different degrees of impairment in their cardiac repolarization reserve, is expected to provide more reliable, and more thorough detection of (multi-channel-based) drug-induced ventricular arrhythmias.

Indeed, it has been shown that LQT1 rabbits lacking *I*~Ks~ and LQT5 rabbits with impaired *I*~Ks~ function were particularly sensitive in identifying *I*~Kr~-blocking properties of drugs; while transgenic LQT2 rabbits lacking I~Kr~ demonstrated a particularly high sensitivity to *I*~Ks~*-* or *I*~K1~-blocking drugs ([@B164]; [@B70]; [@B115]; [@B118]; [@B64]) as further outlined in the following subchapters.

### Investigation of Drug-Induced Changes in Proarrhythmia Markers in Transgenic LQTS Rabbit Models {#s3_4_1}

Drug-induced arrhythmia is a relatively rare event, and arrhythmia development as "hard endpoint" cannot be directly studied---especially during "first-in-human" clinical trials. Therefore, model systems with increased susceptibility for proarrhythmia are employed for safety testing and changes in various proarrhythmia markers are monitored to assess the pro-arrhythmic potential of the investigated/applied drug.

Several biomarkers have been suggested to use for proarrhythmia screening that reflect changes in various aspects of repolarization such as: (i) duration (QTc, APD), (ii) spatial (T~peak-end~, APD dispersion), and (iii) temporal dispersion (STV~QT~, QT/RR steepness, APD restitution) of repolarization (for more details, see previous sections). These were also employed in the different transgenic LQTS rabbit models.

Transgenic LQT2 rabbits demonstrated a high sensitivity to *I*~Ks~*-* or *I*~K1~-blocking anesthetic agents such as isoflurane (*I*~Ks~) or the anxiolytic sedative midazolam (*I*~K1~) as demonstrated by a particularly pronounced prolongation of QT and heart-rate corrected QT index as compared to healthy rabbits ([@B114]) ([**Figure 5A**](#f5){ref-type="fig"}). In addition, a pronounced increase in *in vivo* ECG proarrhythmia markers (QT, STV~QT~, and T~peak-end~) and *ex vivo* monophasic AP related proarrhythmia markers (APD, AP triangulation and APD restitution steepness) indicated higher susceptibility also to other *I*~K1~ and *I*~Ks~ blocking compounds (BaCl~2~ and HMR-1556) in transgenic LQT2 and double-transgenic LQT2--5 rabbits ([@B64]) ([**Figures 5A, B**](#f5){ref-type="fig"}).

![Pro-arrhythmic drug-effects in transgenic LQTS rabbit models: changes in pro-arrhythmia markers. **(A)** Changes in *in vivo* pro-arrhythmia markers. (i.) Bar graphs show changes in QTc, STV~QT~, and T~peak~-T~end~ in anaesthetized animals after i.m. injection of I~Kr~, I~K1~, and I~Ks~-blockers dofetilide, BaCl~2~, HMR-1556, respectively in WT, LQT2, LQT5, and LQT2--5 rabbits \[modified from ([@B64])\]. \*p \< 0.05 inter-genotype comparison, ^\#^p \< 0.05 vs. baseline, T trend p \< 0.1 vs. baseline. (ii.) I~K1~-blocker midazolam-induced change in heart-rate corrected QT-index in free-moving male (solid bars) and female (hatched bars) WT, LQT1, and LQT2 rabbits is also shown. The dashed line represents the mean QT indexes in free-moving rabbits obtained with the genotype-specific correction formula (=100%) \[modified from ([@B114])\]. \*p \< 0.05 vs. free-moving rabbits of the same genotype. (iii.) Bar graphs indicate I~Kr~-blocker dofetilide-induced increase in STV~QT~ in WT and LQT5 animals \[modified from ([@B97])\]. Bsl, baseline; Dof, dofetilide.\*p \< 0.05 inter-genotype comparison, ^\#^p \< 0.05 vs. baseline. **(B)** Changes in *ex vivo* pro-arrhythmia markers. Bar graphs of changes in action potential duration (ΔAPD75), action potential duration/stimulation cycle length ratio (ΔAPD/CL ratio and action potential triangulation (ΔAPD90-30) after 10 min perfusion with I~Kr~, I~K1~ and I~Ks~-blockers dofetilide, BaCl~2~ and HMR-1556, respectively in WT, LQT2, LQT5, and LQT2--5 rabbits. \*p \< 0.05 inter-genotype comparison, ^\#^p \< 0.05 vs. baseline \[modified from ([@B64])\].](fphar-11-00853-g005){#f5}

LQT1 and LQT5 models; on the other hand, were especially sensitive to *I*~Kr~ blockade (dofetilide, E4031, and erythromycin), as demonstrated *in vivo* by a pronounced increase in QTc, STV~QT~, and T~peak-end~ and *ex vivo* by a prolongation of APD and (in LQT1) APD dispersion ([@B115]; [@B181]; [@B97]).

### Investigation of *Ex Vivo* Susceptibility to Arrhythmia in Isolated Transgenic LQTS Rabbit Hearts {#s3_4_2}

The direct assessment of *ex vivo* arrhythmia development in isolated Langendorff-perfused transgenic LQTS rabbit hearts were first performed by Hornyik et al., using different provocation factors---such as bradycardia, low \[K^+^\]~o~, and/or application of K^+^-channel blockers---that are also crucial in drug-induced proarrhythmia formation in the clinical setting ([@B64]). It was shown that the application of *I*~K1~-blocker BaCl~2~ alone already significantly increased the incidence and duration of ventricular extra beats in LQT2 and LQT2--5 hearts ([**Figure 6A**](#f6){ref-type="fig"}). When the pre-existing temporal, beat-to-beat-QT-instability, and the prolonged, regionally heterogeneous repolarization were even further aggravated by lowering the \[K^+^\]~o~, the sensitivity for re-entry formation was increased, leading to significantly longer duration and higher incidence of more malignant type of ventricular arrhythmias (VT and VF) in LQT2 and LQT2--5 but not in healthy WT hearts ([**Figure 6A**](#f6){ref-type="fig"}). In LQT5 hearts with less pronounced reduction of repolarization reserve, only less severe types of ventricular arrhythmias (bigeminy) were detected. These observations of a higher sensitivity of transgenic LQTS hearts to potassium channel blocking drugs than normal WT hearts suggests that the use of different transgenic LQTS rabbits might help in more reliably detect drug-induced proarrhythmia.

![Pro-arrhythmic drug-effects in transgenic LQTS rabbit models: arrhythmia development. **(A)** *Ex vivo* arrhythmia development. Graphs indicating the duration (% of perfusion time) of arrhythmias provoked by perfusing the hearts with low \[K^+^\]~o~ (2 mM) KH, or with combined low \[K^+^\]~o~ (2 mM) KH and I~K1~-blocker BaCl~2~ (10 µM) in WT, LQT5, LQT2 and LQT2--5 animals. Inlets show representative ECG recordings of ventricular escape rhythm (VER), ventricular extra beats (VEB), bigeminy, ventricular tachycardia (VT) and ventricular fibrillation (VF) \[modified from ([@B64])\]. \*p \< 0.05 inter-genotype comparison. **(B)** *In vivo* arrhythmia development. (i.) Bar graphs of dofetilide-induced incidence (in %) and log duration of torsade de pointes (TdP) tachycardia in WT and LQT5 rabbits \[modified from ([@B97])\]. \*p \< 0.05 inter-genotype comparison. (ii.) Episode of polymorphic TdP tachycardia in female LQT2 rabbit during propofol anesthesia (acquired with telemetric ECG) \[modified from ([@B114])\]. (iii.) Episode of dofetilide-induced pVT in male LQT1 rabbit during episode of alternating AV 2:1/3:1 block \[modified from ([@B115])\].](fphar-11-00853-g006){#f6}

### Investigation of *In Vivo* Susceptibility to Arrhythmia of Transgenic LQTS Rabbits {#s3_4_3}

High *in vivo* susceptibility to arrhythmia of transgenic LQTS rabbit models were demonstrated as early as the first characterizations of the models were performed.

In transgenic LQT2 rabbit models, exhibiting regionally heterogeneous prolongation of repolarization, VT and VF easily occurred spontaneously resulting in high SCD rates ([@B19]). In addition, a further reduction of repolarization reserve by the *I*~Ks~-blocker isoflurane or by the *I*~to~-/*I*~Ks~-blocker propofol led to increased proarrhythmia with a variety of arrhythmic events such as AV 2:1 blocks, T-wave alternans, PVCs, bigeminy, and lethal TdP occurring even during short episodes of anesthesia ([@B114]) ([**Figure 6B**](#f6){ref-type="fig"}).

Transgenic LQT1 rabbits with normal/physiological heart rates and/or without organic heart diseases exhibited relatively homogenous prolongation of repolarization in the LV without substantial increase in APD dispersion; therefore, no spontaneous arrhythmias and SCD were detected ([@B19]). When the repolarization reserve of LQT1 rabbits were further challenged by continuous tachypacing or AV-ablation to induce cardiac tachymyopathy ([@B84]), or complete AV-block ([@B77]), respectively, however, significant APD dispersion and discordant alternans developed and VT/VF was easily inducible and even occurred spontaneously ([@B84]). The model also demonstrated the development of pseudo-AV blocks and drug-induced TdP upon *I*~Kr~-blockade by dofetilide and E4031 ([@B115]; [@B181]; [@B97]; [@B182]) ([**Figure 6B**](#f6){ref-type="fig"}).

The recently generated LQT5 model with slight reduction in *I*~Ks~ function similarly demonstrated more pronounced *I*~Kr~-blocker dofetilide induced TdP formation *in vivo* than healthy WT rabbits ([@B97]) ([**Figure 6B**](#f6){ref-type="fig"}).

### Limitations of the Currently Available Models and Outlook {#s3_4_4}

As the "dominant-negative" transgenic strategy was used to generate the LQTS rabbits, instead of a rabbit gene "knock-out"/human transgene "knock in" approach; these models are genetically distinct from LQTS patients. Newly emerging genetic engineering techniques such as CRISPR-cas \[as described in details in ([@B16])\] may help to develop novel---also genetically closer---animal models for these human diseases. As currently available models demonstrate a LQTS phenotype, however, with different degrees of reduction in repolarization reserve and increased susceptibility to arrhythmia both spontaneously and particularly upon drug-induced ion channel blockade, they could still represent valuable models for proarrhythmia safety testing in the context of reduced repolarization reserve.

Furthermore, compensatory electro-mechanical adaptation of cardiomyocytes in response to the altered function ("cardiac remodeling") can also show species differences that could influence their arrhythmia sensitivity. In transgenic LQTS mice, for example, the observed compensatory upregulation of non-affected potassium currents limit their use in identifying repolarizing prolonging---potentially pro-arrhythmic---agents, as opposed to transgenic LQTS rabbits, in which parallel decrease in reciprocal repolarizing current(s) was seen ([@B19]) that even further increased the sensitivity of these models to detect drug-induced proarrhythmia. Currently, very little is known about the nature and extent of these compensatory remodeling processes in human diseases with impaired cardiac repolarization reserve; therefore, it is not known, which animal model mimics most accurately human pathophysiology from this aspect.

In spite of similarities in cardiac ion channels in rabbits and humans, cardiac repolarization is still conveyed through ion channels with slightly different biophysiological characteristics in each species; therefore, caution has to be applied when translating findings based on data from experimental animal models into humans.

Current animal models focus on the detection of repolarization prolonging pro-arrhythmic effects. Drug-induced proarrhythmia may, however, also occur upon pathologically pronounced acceleration/shortening of cardiac repolarization ([@B98]). Here, novel models such as the transgenic short QT syndrome rabbit model ([@B119]), may be particularly useful for the detection of these pro-arrhythmic drug properties.

Further improvement of current *in silico* proarrhythmia screening capabilities by integrating experimental *in vivo*, whole heart, cellular, and ion channel data into computational models are highly warranted ([@B140]; [@B27]), and could potentially lead to better assessment of mutation-specific aspects of a wide range of cardiac channelopathies, since currently available animal models mimicking cardiac channelopathies are very limited.

Importantly, the future use of patient-specific and/or disease-specific human induced pluripotent stem cell derived cardiomyocytes (iPSC-CM) has the potential to become a relevant additional patient/disease-specific *in vitro* safety screening platform to test the pro-arrhythmic potential of novel drug candidates ([@B102]; [@B140]; [@B27]).
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